A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation.
Nikolaos KaramichalakisVasileios KolovosIoannis ParaskevaidisElias TsougosPublished in: Journal of cardiovascular development and disease (2022)
Atrial arrhythmias are common in patients with diabetes mellitus (DM), and despite recent advances in pharmaceutical and invasive treatments, atrial fibrillation (AF) and atrial flutter (AFl) are still associated with substantial mortality and morbidity. Clinical trial data imply a protective effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on the occurrence of AF and AFl. This review summarizes the state of knowledge regarding DM-mediated mechanisms responsible for AF genesis and recurrence but also discusses the recent data from experimental studies, published trials and metanalyses.
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- oral anticoagulants
- clinical trial
- left atrial appendage
- direct oral anticoagulants
- electronic health record
- heart failure
- glycemic control
- percutaneous coronary intervention
- big data
- healthcare
- risk assessment
- type diabetes
- cardiovascular events
- phase ii
- open label
- risk factors
- skeletal muscle
- machine learning
- coronary artery disease
- double blind
- weight loss
- deep learning